Loading clinical trials...
Loading clinical trials...
Evaluation of the safety and tolerability of escalating doses of NR1 administered intracerebrally at a single time-point post-injury to subjects with chronic ISS with or without cortical stroke.
Keep your clinical trial research organized — questions to ask, what to expect, and key details.
Lead Sponsor
Gary Steinberg, MD, PhD
Collaborators
NCT07491952 · Ischemic Stroke, Acute Stroke
NCT05293080 · Acute Ischemic Stroke, Atrial Fibrillation
NCT05600374 · Ischemic Stroke, Acute
NCT06740942 · Acute Ischemic Stroke, Transient Ischemic Attack
NCT06292117 · Ischemic Stroke, CYP2C19 Polymorphism
Stanford Health Center
Stanford, California
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions